Lumiracoxib, a highly selective COX-2 inhibitor

References

• Topol EJ. Arthritis medicines and cardiovascular events –"house of coxibs". JAMA 293(3), 366–368 (2005).
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364(9435), 665–674 (2004).
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435), 675–684 (2004).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib – study design and patient demographics. Aliment Pharmacol. Ther. 20(1), 51–63 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am. J. Cardiol. 89(6A), 26D–32D (2002).
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18(7), 790–804 (2004).
   PubMed Web of Science ®Google Scholar
• Flower RJ. The development of COX2 inhibitors. Nature Rev. Drug Discov. 2(3), 179–191 (2003).
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345(6), 433–442 (2001).
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340(24), 1888–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab. Dispos. 32(5), 566–5671 (2004).
   PubMed Web of Science ®Google Scholar
• Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand. J. Rheumatol. 33(1), 1–6 (2004).
   PubMed Web of Science ®Google Scholar
• Weaver ML, Flood DJ, Kimble EF, Fujimoto RA. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Annual European Congress of Rheumatology, Lisbon, Portugal (2003) (Abstract 44).
   Google Scholar
• Dawson J, Jagher B, Toscano KT, Fujimoto RA, Quadros E. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib. Annual European Congress of Rheumatology, Lisbon, Portugal (2003) (Abstract 42).
   Google Scholar
• Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Annual European Congress of Rheumatology, Stockholm, Sweden (2002) (Abstract 300).
   Google Scholar
• Rordorf C, Scott G, Milosavljev S, Blood P, Branson J, Greig G. Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX189 in healthy subjects. Annual European Congress of Rheumatology, Stockholm, Sweden (2002) (Abstract 284).
   Google Scholar
• Wilding IR, Connor AL, Carpenter P et al. Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. Pharm. Res. 21(3), 443–446 (2004).
   PubMed Web of Science ®Google Scholar
• Esser R, Berry C, Du Z et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol. 144(4), 538–550 (2005).
   PubMed Web of Science ®Google Scholar
• Scott G, Branson J, Milosavljev S et al. Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee. Annual European Congress of Rheumatology (2003) (Abstract 235).
   Google Scholar
• Scott G, Rordorf C, Reynolds C et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin. Pharmacokinet. 43(7), 467–478 (2004).
   PubMed Web of Science ®Google Scholar
• Patrignani P, Campestrini J, Branson J et al. Lumiracoxib is a selective inhibitor of cyclooxygenase-2 in patients with osteoarthritis. Annual European Congress of Rheumatology, Berlin, Germany (2004) (Abstract 412).
   Google Scholar
• Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29(8), 1039–1049 (1986).
   PubMed Web of Science ®Google Scholar
• Altman R, Alarcon G, Appelrouth D et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 33(11), 1601–1610 (1990).
   PubMed Web of Science ®Google Scholar
• Altman R, Alarcon G, Appelrouth D et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 34(5), 505–514 (1991).
   PubMed Web of Science ®Google Scholar
• Grifka J, Zacher J, Brown J et al. Lumiracoxib is effective and well tolerated in patients with osteoarthiritis of the hand: results from a randomized, placebo-controlled trial. Annual Europan Congress of Rheumatology, Lisbon, Portugal (2003) (Abstract 222).
   Google Scholar
• Schell E, Boucher L, Tamasi L, Ouellet J, Moore A, Lee A. Long-term efficacy and tolerability of lumiracoxib in osteoarthritis of the knee. Annual European Congress of Rheumatology, Lisbon, Portugal (2003) (Abstract 224).
   Google Scholar
• Fleischmann R, Sheldon E, Maldonado Cocco J, Yu S, Dutta D, Usiskin K. A prospective randomized 13-week study evaluating the efficacy of lumiracoxib in patients with osteoarthritis of the knee. European Annual Congress of Rheumatology, Lisbon, Portugal (2003) (Abstract 233).
   Google Scholar
• Tannenbaum H, Berenbaum F, Reginster JY et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann. Rheum. Dis. 63(11), 1419–1426 (2004).
   PubMed Web of Science ®Google Scholar
• Lehmann R, Brzosko M, Kopska P et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr. Med. Res. Opin. 21(4), 517–526 (2005).
   PubMed Web of Science ®Google Scholar
• Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin. Ther. 27(1), 64–77 (2005).
   PubMedGoogle Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15(12), 1833–1840 (1988).
   PubMed Web of Science ®Google Scholar
• Bellamy N, Campbell J, Haraoui B et al. Dimensionality and clinical importance of pain and disability in hand osteoarthritis: development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. Osteoarthritis Cartilage 10(11), 855–862 (2002).
   PubMed Web of Science ®Google Scholar
• Pham T, Van Der Heijde D, Lassere M et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J. Rheumatol. 30(7), 1648–1654 (2003).
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 35(5), 498–502 (1992).
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31(3), 315–324 (1988).
   PubMed Web of Science ®Google Scholar
• Geusens P, Alten R, Rovensky J et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int. J. Clin. Pract. 58(11), 1033–1041 (2004).
   PubMed Web of Science ®Google Scholar
• Pavelka K, Nayiager S, Kivitz A, Patel N, Yu S, Sloan V. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13-week, randomized, double-blind study. Annual European Congress of Rheumatology, Berlin, Germany (2004) (Abstract 107).
   Google Scholar
• Kellstein D, Ott D, Jayawardene S, Fricke J. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int. J. Clin. Pract. 58(3), 244–250 (2004).
   PubMed Web of Science ®Google Scholar
• Chan V, Clark A, Davis J. A comparison of COX189, naproxen and placebo for relief of post-orthopedic surgery pain. World Congress of Pain, San Diego, CA, USA (2002) (Abstract 951-P221).
   Google Scholar
• Bitner M, Kattenhorn J, Hatfield C, Gao J, Kellstein D. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int. J. Clin. Pract. 58(4), 340–345 (2004).
   PubMedGoogle Scholar
• Headache ClassificationSubcommittee of the International Headache Society.The International Classification of Headache Disorders, second edition. Cephalalgia 24(Suppl 1.), 9–160 (2004).
   PubMedGoogle Scholar
• Packman E, Packman B, Thurston H, Tseng L, Kellstein D. Lumiracoxib, a novel COX-2 selective inhibitor, is effective in the treatment of episodic tension-type headache. Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society, Vancouver, Canada (2004) (Abstract 810).
   Google Scholar
• Hawkey CJ. The Prevention of Ulcers with COX189 Compared with Ibuprofen in NSAID Investigation (PUCCINI) Group. Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients. Digestive Disease Week, San Francisco, CA, USA (2002) (Abstract M1732).
   Google Scholar
• Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Ailment Pharmacol. Ther. 19(11), 1189–1198 (2004).
   PubMed Web of Science ®Google Scholar
• Hawkey C, Hoexter G, Richard D, Gitton X, Weinstein W. Lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, has improved gastrointestinal safety and tolerability compared with non-selective nonsteroidal anti-inflammatory drugs: a pooled analysis. American College of Rheumatology Annual Scientific Meeting, Orlando, FL, USA (2003) (Abstract 87).
   Google Scholar
• Hirschberg R, Della Casa Alberighi O, Hoexter G. Effect of lumiracoxib on blood pressure and fluid retention: pooled analysis. British Society for Rheumatology Annual Meeting, Edinburgh, UK (2004) (Abstract 123).
   Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. Br. Med. J. 308(6921), 81–106 (1994)
   PubMed Web of Science ®Google Scholar